24/7 Market News Snapshot 02 May, 2025 – Adial Pharmaceuticals, Inc (NASDAQ:ADIL)

May 2, 2025

DENVER, Colo., 02 May, 2025 (www.247marketnews.com) – (NASDAQ:ADIL) are discussed in this article.
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL), a clinical-stage biopharmaceutical company committed to developing innovative therapies for addiction and related disorders, is currently trading at $0.861, reflecting a decline of approximately 10.38% from a previous session close of $0.780. This volatility is evidenced by a trading volume of 20.40 million shares, suggesting heightened market activity and bearish sentiment around the stock. Investors are encouraged to closely monitor potential support levels and volume indicators, as these elements are crucial in assessing future price movements and market dynamics.

In a strategic move to enhance its capital structure, Adial has announced a warrant inducement agreement with a prominent healthcare-focused institutional investor. This agreement facilitates the immediate exercise of existing Series B and Series C Warrants, enabling the acquisition of up to 1,418,440 shares and 2,300,000 shares of the company’s common stock, respectively, at a reduced exercise price of $0.74. This initiative is expected to generate approximately $2.75 million in gross cash proceeds, which will be directed towards working capital and other general corporate purposes. A.G.P./Alliance Global Partners has been appointed as the financial advisor for this transaction.

As part of the agreement, the investor will receive new unregistered Series B-1 and Series C-1 Warrants in exchange for the exercise of the existing warrants. These new warrants allow for the purchase of an additional 2,482,270 and 4,025,000 shares of common stock at the same exercise price, with respective expiration periods set at five years and eighteen months post-stockholder approval.

The anticipated closing date for this transaction is around May 5, 2025, subject to customary closing conditions. With this move, Adial Pharmaceuticals is strengthening its financial foundation while continuing to advance its lead investigational product, AD04, aimed at treating Alcohol Use Disorder (AUD) and other similar conditions. Encouraging results from the ONWARD™ pivotal Phase 3 clinical trial underscore the company’s potential to revolutionize treatment options for addiction.

Related news for (ADIL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.